

Evaluation of the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in Renal cancer

Yutong Wu^{1,2,3#}, Yingqi Li^{1,2,4}, Huimei Zhou^{1,2,5#}, Chen Sun^{1,2,5}, Xutai Li^{1,2,5#}, Zhenjian Ge^{1,2,3}, Wenkang Chen^{1,2,3}, Shengjie Lin^{1,2,3}, Pengwu Zhang^{1,2}, Wuping Wang^{1,2,4}, Siwei Chen^{1,2,4}, Wei Li⁶, Lingzhi Tao^{1,2*}, Xionghui Wu^{1,2*}, Liangkuan Bi^{1,2*}, Yongqing Lai^{1,2*}

1 Department of Urology, Peking University Shenzhen Hospital, Shenzhen, 518036; 2Institute of Urology, Shenzhen Peking University-The Hong Kong University of Science and Technology Medical Center, Shenzhen, 518036; 3 Shantou University Medical College, Shantou, Guangdong 515041; 4 Shenzhen University Health Science Center, Shenzhen, China 518055; 5 The Fifth Clinical Medical College of Anhui Medical University, Hefei 230032; 6 Shenzhen KeRuiDa Health Technology Co., Ltd., Shenzhen, 518071.

Contributed equally to this work.

*Corresponding author: Yongqing Lai, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: yqlord@163.com; Liangkuan Bi, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: biliangkuan@126.com; Xionghui Wu, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: 13802260619@163.com; Lingzhi Tao, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, E mail: 520111058@qq.com.

Background: Renal cancer is a serious threat to human health and causes heavy economic burden. Ultrasound is widely used in screening or preliminary diagnosis of renal tumors, and enhanced CT is widely used in the diagnosis of renal tumors. However, false-positive results of ultrasound and enhanced CT will bring unnecessary mental pain, expensive examination costs, physical injuries, and even adverse consequences such as organ removal and loss of function; while false-negative results of enhanced CT bring delayed treatment, and patients will thus have to bear the adverse consequences of poor prognosis, high treatment costs, poor quality of life, and short survival period. There is an urgent need to find convenient, cost-effective and non-invasive diagnostic methods to reduce the false-positive rate of ultrasound and the false-negative and false-positive rates of enhanced CT in renal tumors. The aim of this study was to evaluate the diagnostic value of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D in renal tumors.

Patients and methods: 298 subjects (malignant group, n=233; benign group, n=65) were finally included in this study. Remaining serum samples from the subjects were collected and tested by applying the YiDiXie™ all-cancer detection kit to evaluate the sensitivity and specificity of YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D, respectively.

Results: The sensitivity of YiDiXie™-SS in renal ultrasound-positive patients was 98.3% (95% CI: 95.7% - 99.3%; 229/233) with a specificity of 66.2% (95% CI: 54.0% - 76.5%; 43/65). Compared to the application of enhanced CT alone, sequential use of YiDiXie™-SS and CT had comparable sensitivity, but the false positive rate decreased from 21.5% (95% CI: 13.3% - 33.0%; 14/65) to 6.2% (95% CI: 2.4% - 14.8%; 4/65). This means that the application of YiDiXie™-SS reduced the false-positive rate of ultrasound by 66.2% (95% CI: 54.0% - 76.5%; 43/65) and the false-positive rate of enhanced CT by 71.4% with essentially no increase in malignancy leakage. The sensitivity of YiDiXie™-HS in patients with a negative enhanced CT was 86.1% (95% CI: 71.3% - 93.9%; 31/36) and specificity was 84.3% (95% CI: 72.0% - 91.8%; 43/51). This means that YiDiXie™-HS reduced the false-negative rate of enhanced CT by 86.1% (95% CI: 71.3% - 93.9%; 31/36). YiDiXie™-D had a sensitivity of 29.4% (95% CI: 23.5% - 36.2%; 58/197) and a specificity of 92.9% (95% CI: 68.5% - 99.6%) in patients with positive enhanced CT. This means that YiDiXie™-D reduces the false positive rate of enhanced CT by 92.9% (95% CI: 68.5% - 99.6%; 13/14).

Conclusion: YiDiXie™-SS dramatically reduces the false-positive rate of ultrasound and enhanced CT with essentially no increase in delayed treatment of malignant tumors. YiDiXie™-HS dramatically reduces the false-negative rate of enhanced CT. YiDiXie™-D dramatically reduces the false-positive rate of enhanced CT. The YiDiXie™ test has significant diagnostic value in renal tumors, and is expected to solve the 3 problems of "high false-positive rate of ultrasound", "high false-negative rate of enhanced CT" and "high false-positive rate of enhanced CT".

Clinical trial number: ChiCTR2200066840. **has not been certified by peer review and should not be used to guide clinical practice.**

Key words: Renal cancer, Ultrasound, Enhanced CT, False-positive, False-negative, YiDiXie™-SS, YiDiXie™-HS, YiDiXie™-D

INTRODUCTION

Renal cancer is one of the common malignant tumors of the urinary system¹. The latest data show that there are 434,419 new kidney cancer cases and 155,702 new deaths worldwide in 2022²; compared with 2020, the incidence rate of RCC increased by 0.7% in 2022³, which is still showing a trend of increasing year by year. Since renal cancer is insensitive and less effective to treatments such as radiotherapy and chemotherapy, and is prone to metastasis and recurrence, surgical resection is still considered the most effective treatment for limited renal cancer without metastasis⁴. Renal cancer has an insidious onset with no specific clinical manifestations in the early stage, and about 33% of patients have already developed distant metastasis at the time of the first visit⁵, and 20%-30% of patients develop recurrence at postoperative follow-up⁶. Studies have shown that the 5-year survival rate for stage I kidney cancer can be as high as 84%-90%, compared to only 6% for stage IV kidney cancer⁷. Through early screening, not only the prognosis of patients can be improved, but also the economic burden of patients can be reduced⁸. Thus, kidney cancer is a serious threat to human health.

Ultrasound is widely used in the screening or initial diagnosis of renal tumors due to its sophistication, affordability, non-invasiveness and lack of exposure to radiation⁹. Ultrasound has a low specificity for detecting renal cancer^{10,11} and therefore can produce a large number of false positive results. When renal ultrasound is positive, patients usually undergo enhanced CT. False-positive renal ultrasound results mean that the patient is subjected to an unnecessarily expensive and radiologic test and potentially incorrect surgical procedure, and the patient will have to bear the consequences of mental anguish, costly tests and procedures, radiologic injuries, and surgical injuries. Therefore, there is an urgent need to find a convenient, cost-effective and non-invasive diagnostic method to reduce the false-positive rate of renal tumor ultrasound.

Enhanced CT is widely used in the diagnosis of renal tumors. On the one hand, enhanced CT can produce a large number of false-positive results. The false-positive rate of enhanced CT in smaller renal tumors can reach 15-30%^{12,13}. When enhancement CT is positive, patients usually undergo tumor resection or radical resection⁴. A false-positive result on enhanced CT means that a benign disease is misdiagnosed as a malignant tumor, and the patient will have to bear the undesirable consequences of unnecessary mental anguish, costly surgeries and investigations, physical injuries, and even organ removal and loss of function. Therefore, there is an urgent need to find a convenient, cost-effective and noninvasive diagnostic method to reduce the false-positive rate of enhanced CT for renal tumors.

On the other hand, enhanced CT can produce a large number of false negative results. The sensitivity of enhanced CT for diagnosing renal cancer is less than 80%¹⁴. The imaging characteristics of enhanced CT make it less accurate in evaluating renal tumors <5 cm, with a false-negative rate of 28%¹⁵. When enhancement CT is negative, patients are usually taken to observation, with regular follow-up⁴. Its false-negative result means that the malignancy has been missed and will likely lead to a delay in treatment, progression of the malignancy, and possibly even development of an advanced stage. Patients will thus have to bear the adverse consequences of poor prognosis, high treatment costs, poor quality of life, and short survival. Therefore, there is an urgent need to find a convenient, economical and noninvasive diagnostic method to reduce the false-negative rate of enhanced CT for renal tumors.

Based on the detection of novel tumor markers of miRNA in serum, Shenzhen KeRuiDa Health Technology Co., Ltd. has developed an in vitro diagnostic test, YiDiXie™ all-cancer test (hereinafter referred to as YiDiXie™ test), which can detect multiple types of cancers with only 200

microliters of whole blood or 100 microliters of serum each time. The YiDiXie™ test consists of three different tests, YiDiXie™-HS, YiDiXie™-SS and YiDiXie™-D¹⁶.

PATIENTS AND METHODS

Study design

This work is part of the sub-study "Evaluating the diagnostic value of the YiDiXie™ test in multiple tumors" of the SZ-PILOT study (ChiCTR2200066840).

The SZ-PILOT study (ChiCTR2200066840) is a single-center, prospective, observational study. Participants who signed a general informed consent for donation of remaining samples at the time of admission or physical examination were included, and whose remaining serum samples of 0.5 ml were collected for use in this study.

The study was blinded. Both the laboratory personnel who performed the YiDiXie™ test and

Participants

Subjects with positive renal ultrasound were included in this study. The two groups of participants were enrolled separately and all participants who met the inclusion criteria were included consecutively.

The present study initially included hospitalized patients with "suspected (solid or hematological) malignancy" who signed a general informed consent for donation of the remaining samples. Participants with a postoperative pathological diagnosis of "malignant tumor" were

Sample collection, processing

The serum samples used in this study were obtained from serum left over after a normal clinic visit, without the need for additional blood draws. Approximately 0.5 ml of serum samples were

"YiDiXie™ test"

The YiDiXie™ test is performed through the YiDiXie™ all-cancer detection kit, an in-vitro diagnostic kit developed and manufactured by Shenzhen KeRuiDa Health Technology Co.. The kit

The purpose of this study was to evaluate the diagnostic value of three tests of the YiDiXie™ test, YiDiXie™-SS, YiDiXie™-HS, and YiDiXie™-D, in renal tumors.

the KeRuiDa laboratory technicians who adjudicated the results of the YiDiXie™ test were unaware of the subjects' clinical information. The clinical experts who evaluated the subjects' clinical information were also unaware of the results of the YiDiXie™ test.

The study was approved by the Ethics Committee of Peking University Shenzhen Hospital and was conducted in accordance with the International Conference on Harmonization for "Good clinical practice guidelines" and the Declaration of Helsinki.

included in the malignant group, and those with a postoperative pathological diagnosis of "benign tumor" were included in the benign group. Subjects with ambiguous pathologic results were excluded from the study. Some of the samples from the malignant group were used in our previous work¹⁶.

Participants failing the serum sample quality test prior to the YiDiXie™ test were excluded from this study. For details of enrollment and exclusion, please refer to our previous work¹⁶.

collected from the remaining serum of subjects in the Medical Laboratory and stored at -80°C for use in the subsequent YiDiXie™ test.

detects the expression levels of dozens of miRNA biomarkers in the serum to judge the presence or absence of cancer in the subject's body. An appropriate threshold is predefined for each

miRNA biomarker to ensure that each miRNA marker is highly specific, and these independent assays are integrated in a concurrent assay format to dramatically increase the sensitivity of broad-spectrum cancers and maintain high specificity.

The YiDiXie™ test consists of three distinct assays: YiDiXie™-HS, YiDiXie™-SS, and YiDiXie™-D. YiDiXie™-Highly Sensitive (YiDiXie™-HS) has been developed with a balance of sensitivity and specificity. YiDiXie™-Super Sensitive (YiDiXie™-SS) significantly increases the number of miRNA tests to achieve extremely high sensitivity for all clinical

Diagnosis of Enhanced CT

The diagnostic conclusion of the enhanced CT is judged to be "positive" or "negative". If the diagnostic conclusion is positive, relatively positive, or favors a malignant tumor, the test result is

Extraction of clinical data

The clinical, pathological, laboratory, and imaging data included in this study were drawn from the subjects' hospitalized medical records or physical examination reports. The clinical staging

Statistical analyses

Descriptive statistics were reported for demographic and baseline characteristics. For categorical variables, the number and percentage of subjects in each category were calculated; for continuous variables, the total number of subjects (n), mean, standard deviation (SD) or standard

stages of all malignant tumor types. YiDiXie™-Diagnosis (YiDiXie™-D) drastically enhances the diagnostic thresholds of individual miRNA tests to achieve extremely high specificity for all malignant tumor types.

The YiDiXie™ test was conducted following the instructions for the YiDiXie™ all-cancer detection kit. Detailed procedures are described in our previous work¹⁶.

The original results were analyzed by the laboratory technicians of Shenzhen KeRuiDa Health Technology Co., Ltd and the results of the YiDiXie™ test were determined to be "positive" or "negative".

considered "positive". If the diagnosis is positive, more positive, or favors a benign tumor, or if the diagnosis is ambiguous, the result is considered "negative".

was completed by trained clinicians assessed according to the AJCC staging manual (7th or 8th edition)^{17,18}.

error (SE), median, first quartile (Q1), third quartile (Q3), minimum, and maximum values were calculated. 95% confidence intervals (CI) for multiple indicators were calculated using the Wilson (score) method.

RESULTS

Participant disposition

298 participants were finally included in this study (malignant group, n=233; benign group, n=65). The demographic and clinical characteristics of the 298 participants in the study are presented in Table 1.

The two groups of study subjects were comparable in terms of demographic and clinical characteristics (Table 1). The mean (standard deviation) age was 51.2 (13.26) years and 41.9% (125/298) were female.

Table 1. Participants' demographic and clinical manifestation

	Cancer (n =233)	Benign (n =65)	Total (N = 298)
Age, years			
Mean (SD)	53.1 (12.75)	44.2 (12.76)	51.2 (13.26)
Median (Q1,Q3)	54 (44, 64)	42 (35, 54)	51 (41, 62)
Min, max	19, 83	19, 68	19, 83
Age, group, n (%)			
< 50	91 (39.1)	41 (63.1)	132 (44.3)
≥ 50	142 (60.9)	24 (36.9)	166 (55.7)
< 65	181 (77.7)	61 (93.8)	242 (81.2)
≥ 65	52 (22.3)	4 (6.2)	56 (18.8)
Sex, n (%)			
Female	72 (30.9)	53 (81.5)	125 (41.9)
Male	161 (69.1)	12 (18.5)	173 (58.1)
Body mass index (kg/m2)			
n	143	61	204
Mean (SD)	24.3 (3.71)	22.6 (3.48)	23.8 (3.71)
Median (Q1,Q3)	24.2 (21.5, 26.1)	22.3 (20.1, 25.0)	23.7 (20.7, 25.8)
Min, max	16.4 39.7	17.8 31.2	16.4 39.7
Body mass index category, n (%)			
Underweight	4 (1.7)	6 (9.2)	10 (3.4)
Benign	63 (27.0)	35 (53.8)	98 (32.9)
Overweight	53 (22.7)	15 (23.1)	68 (22.8)
Obese	23 (9.9)	5 (7.7)	28 (9.4)
Missing	90 (38.6)	4 (6.2)	94 (31.5)
AJCC clinical stage			
Stage I	199 (85.4)		199 (85.4)
Stage II	34 (14.6)		34 (14.6)

Q1,Q3, first quartile, third quartile; SD, standard deviation.

Diagnostic performance of enhanced CT in patients with positive renal ultrasound

As shown in Table 2, the sensitivity of enhanced CT was 84.5% (95% CI: 79.4% - 88.6%; 197/233) and its specificity was 78.5% (95% CI: 67.0% - 86.7%; 51/65).

Table 2. Performance of CT in renal ultrasound-positive patients

	Cancer	Benign	Total
	233	65	298
Positive	197	14	211
Negative	36	51	87

SEN = 197/233 = 84.5% (79.4% - 88.6%) SPE = 51/65 = 78.5% (67.0% - 86.7%)

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

Diagnostic performance of sequential use of YiDiXie™-SS and CT in patients with positive renal ultrasound

In order to address the challenge of high false-positive rate of renal ultrasound, YiDiXie™-SS was applied to renal ultrasound-positive patients.

As shown in Table 3, the sensitivity of YiDiXie™-SS was 98.3% (95% CI: 95.7% - 99.3%; 229/233) and its specificity was 66.2% (95% CI: 54.0% - 76.5%;

43/65).

This means that the application of YiDiXie™-SS reduces the false-positive rate of renal ultrasound by 66.2% (95% CI: 54.0% - 76.5%; 43/65) with essentially no increase in malignant leakage.

Table 3. Performance of YiDiXie™-SS in renal ultrasound-positive patients

	Cancer	Benign	Total
	233	65	298
Test positive	229	22	251
Test negative	4	43	47

SEN = 229/233 = 98.3% (95.7% - 99.3%) SPE = 43/65 = 66.2% (54.0% - 76.5%)

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

To further identify the benign and malignant renal tumors, enhanced CT was applied to YiDiXie™-SS-positive patients. As shown in Table 4, the sensitivity of enhanced CT was 84.7% (95% CI: 79.5% - 88.8%; 194/229) and its specificity was 81.8% (95% CI: 61.5% - 92.7%; 18/22).

Table 5 shows the diagnostic performance of sequential use of YiDiXie™-SS and CT in patients with positive renal ultrasound. As shown in Table 5, the sensitivity of sequential use of YiDiXie™-SS and

CT was 83.3% (95% CI: 77.9% - 87.5%; 194/233), and its specificity was 93.8% (95% CI: 85.2% - 97.6%; 61/65).

This means that the application of YiDiXie™-SS reduced the enhanced CT false-positive rate from 21.5% (95% CI: 13.3% - 33.0%; 14/65) (Table 2) to 6.2% (95% CI: 2.4% - 14.8%; 4/65) with essentially no increase in the leakage of malignant tumors, decreasing the false-positive rate of enhanced CT by 71.4%.

Table 4. Performance of CT in patients with positive YiDiXie™-SS results

	Cancer	Benign	Total
	229	22	251
Positive	194	4	198
Negative	35	18	53

SEN = 194/229 = 84.7% (79.5% - 88.8%) SPE = 18/22 = 81.8% (61.5% - 92.7%)

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

Table 5. Performance of sequential use of YiDiXie™-SS and CT

	Cancer	Benign	Total
	233	65	298
Test positive	194	4	198
Test negative	39	61	100

SEN = 194/233 = 83.3% (77.9% - 87.5%) SPE = 61/65 = 93.8% (85.2% - 97.6%)

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

Diagnostic Performance of YiDiXie™-HS in Enhanced CT Negative Patients

In order to solve the challenge of high rate of missed diagnosis in enhanced CT, YiDiXie™-HS was applied to patients with negative enhanced CT.

As shown in Table 6, the sensitivity of YiDiXie™-HS was 86.1% (95% CI: 71.3% - 93.9%; 31/36) and its

specificity was 84.3% (95% CI: 72.0% - 91.8%; 43 /51).

This means that the application of YiDiXie™-HS reduces the false-negative rate of enhanced CT by 86.1% (95% CI: 71.3% - 93.9%; 31/36).

Table 6. Performance of YiDiXie™-HS in patients with negative CT results

	Cancer	Benign	Total
	36	51	87
Positive	31	8	39
Negative	5	43	48

SEN = 31/36 = 86.1% (71.3% - 93.9%) SPE = 43/51 = 84.3% (72.0% - 91.8%)

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

Diagnostic Performance of YiDiXie™-HS in Enhanced CT Negative Patients

False-positive consequences are significantly worse than false-negative consequences in certain patients with renal tumors, so YiDiXie™-D is applied to these patients to reduce their false-positive rate.

As shown in Table 7, the sensitivity of YiDiXie™

-D was 29.4% (95% CI: 23.5% - 36.2%; 58/197) and its specificity was 92.9% (95% CI: 68.5% - 99.6%; 13/14).

This means that YiDiXie™-SS reduces the false positive rate of enhanced CT by 92.9% (95% CI: 68.5% - 99.6%; 13/14).

Table 7. Performance of YiDiXie™-D in patients with positive CT results

	Cancer	Benign	Total
	197	14	211
Positive	58	1	59
Negative	139	13	152

SEN = 58/197 = 29.4% (23.5% - 36.2%) SPE = 13/14 = 92.9% (68.5% - 99.6%)

SEN, Sensitivity. SPE, Specificity. Two-sided 95% Wilson confidence intervals were calculated.

DISCUSSION

Clinical significance of YiDiXie™-SS in renal ultrasound-positive patients

The YiDiXie™ test consists of three tests with very different characteristics: YiDiXie™-HS, YiDiXie™-SS and YiDiXie™-D¹⁶. YiDiXie™-HS balances sensitivity and specificity with high sensitivity and specificity, while YiDiXie™-SS has very high sensitivity for all types of malignant tumors, but has a slightly lower level of specificity¹⁶. The YiDiXie™-D has very high specificity for all malignant tumor types, but low sensitivity¹⁶.

In patients with positive renal ultrasound, the sensitivity and specificity of further diagnostic methods are important. The trade-off between sensitivity and specificity is essentially a trade-off between the "danger of missing malignant tumors" and the "danger of misdiagnosing benign tumors". In general, false-positive renal ultrasound is usually treated with enhanced CT but not surgery. Therefore, false-positive renal tumor ultrasound does not lead to serious consequences such as surgical trauma, organ removal, or loss of function. Thus, the "risk of malignant tumor underdiagnosis" is much higher than the "risk of benign tumor misdiagnosis" in patients with positive renal ultrasound. Therefore, YiDiXie™-SS, which has a very high sensitivity but a slightly lower specificity, was chosen to reduce the false-positive rate of renal tumor ultrasound.

As shown in Table 3, the sensitivity of YiDiXie™-SS in renal ultrasound-positive patients was 98.3% (95% CI: 95.7% - 99.3%; 229/233) with a specificity of 66.2% (95% CI: 54.0% - 76.5%; 43/65). These results

indicate that YiDiXie™-SS reduces the false-positive rate in renal ultrasound-positive patients by 66.2% (95% CI: 54.0% - 76.5%; 43/65) with essentially no increase in malignant tumor underdiagnosis.

YiDiXie™-SS has another important diagnostic value. Compared with enhanced CT alone, sequential use of YiDiXie™-SS and CT had comparable sensitivity, but the false-positive rate was reduced from 21.5% (95% CI: 13.3% - 33.0%; 14/65) to 6.2% (95% CI: 2.4% - 14.8%; 4/65) (Tables 2 and 5). This means that the application of YiDiXie™-SS reduces the false-positive rate of enhanced CT by 71.4% with essentially no increase in malignancy leakage.

The above results imply that YiDiXie™-SS substantially reduces the probability of erroneous enhanced CT and subsequent surgery for benign renal tumors without essentially increasing the number of malignant tumors that are underdiagnosed. In other words, YiDiXie™-SS substantially reduces the mental suffering, expensive examination and surgical costs, radiological injuries, surgical injuries, and other undesirable consequences for patients with false-positive ultrasound examinations of renal tumors in the case of basically no increase in delayed treatment of malignant tumors. Therefore, YiDiXie™-SS satisfies the clinical needs well and has important clinical significance and wide application prospects.

Clinical significance of YiDiXie™-HS in patients with negative enhanced CT

For patients with negative enhanced CT, both the sensitivity and specificity of further diagnostic methods are important. To balance both the sensitivity and specificity is essentially to balance the "danger of underdiagnosis of malignant tumors" and the "danger of misdiagnosis of benign tumors". Higher false-negative rates mean that more malignant tumors are underdiagnosed, leading to delayed treatment and progression of

malignant tumors, which may even develop into advanced stages. As a result, patients will have to bear the adverse consequences of poor prognosis, short survival, poor quality of life, and high cost of treatment.

In general, when benign renal tumors are misdiagnosed as malignant tumors, they usually undergo tumor resection or radical resection, which does not affect the patient's prognosis, and

their treatment costs are much lower than those of advanced cancers. Therefore, in patients with negative enhanced CT, the "risk of malignant tumor misdiagnosis" is higher than the "risk of benign tumor misdiagnosis". Therefore, YiDiXie™-HS, with its high sensitivity and specificity, was chosen to reduce the false-negative rate of enhanced CT for renal tumors.

As shown in Table 6, the sensitivity of YiDiXie™-HS was 86.1% (95% CI: 71.3% - 93.9%; 31/36) and the specificity was 84.3% (95% CI: 72.0% - 91.8%; 43/51). These results indicate that the application

of YiDiXie™-HS reduced the false-negative rate of enhanced CT by 86.1% (95% CI: 71.3% - 93.9%; 31/36).

The above results imply that YiDiXie™-HS substantially reduces the probability of missed malignant tumors with negative enhancement CT. In other words, YiDiXie™-HS substantially reduces the poor prognosis, high treatment cost, poor quality of life, and short survival of patients with false-negative enhanced CT. Therefore, YiDiXie™-HS fulfills the clinical needs well and has important clinical significance and wide application prospects.

Clinical significance of YiDiXie™-D in patients with positive enhanced CT

Patients with positive enhanced CT for renal tumors usually undergo resection of the mass or radical resection. However, there are some conditions that require extra caution in choosing whether to operate or not, hence further diagnosis, e.g., smaller tumors, tumors with difficulty in preserving the kidney, tumors requiring radical surgery, tumors in isolated kidneys, contralateral renal insufficiency, total renal insufficiency, and patients in poor general condition.

In patients with positive enhanced CT for renal tumors, the sensitivity and specificity of further diagnostic methods are both critical. Trading off both the sensitivity and specificity is essentially a trade-off between the "danger of malignant tumors being missed" and the "danger of benign tumors being misdiagnosed". Since smaller tumors have a lower risk of tumor progression and distant metastasis, the "risk of malignant tumor underdiagnosis" is much lower than the "risk of benign tumor misdiagnosis". As for tumors with difficulty in preserving kidney and tumors requiring radical surgery, because the affected side of the kidney needs to be removed, the "risk of misdiagnosis of benign tumors" is much higher than the "risk of malignant tumor misdiagnosis". In patients with isolated kidney, contralateral renal insufficiency or total renal insufficiency, the risk of renal insufficiency or even the need for dialysis

after surgery is higher, so the "harm of misdiagnosis of benign tumors" is much higher than the "harm of malignant tumor underdiagnosis". As for patients with poor general conditions, the risk of misdiagnosis of benign tumors is much higher than that of malignant tumors because the perioperative risk is much higher than that of general conditions. Therefore, for these patients, YiDiXie™-D, which is very specific but less sensitive, was chosen to reduce the false-positive rate of enhanced CT for renal tumors.

As shown in Table 7, YiDiXie™-D had a sensitivity of 29.4% (95% CI: 23.5% - 36.2%; 58/197) and a specificity of 92.9% (95% CI: 68.5% - 99.6%; 13/14). The results above indicate that YiDiXie™-SS reduced the false-positive rate of enhanced CT by 92.9% (95% CI: 68.5% - 99.6%; 13/14).

The above results imply that YiDiXie™-D substantially reduces the probability of wrong surgery for these patients that require additional caution in surgery. In other words, YiDiXie™-D substantially reduces the risk of adverse outcomes such as surgical trauma, organ removal, renal insufficiency, renal dialysis, and even death and other serious perioperative complications in these patients. Therefore, YiDiXie™-D satisfies the clinical needs well and has important clinical significance and wide application prospects.

YiDiXie™ test has the potential to solve three challenges of renal tumor

First of all, the 3 tests of the YiDiXie™ test are of clinical importance in renal tumors. As mentioned earlier, YiDiXie™-SS, YiDiXie™-HS and YiDiXie™-D have significant diagnostic value in patients with positive ultrasound, negative enhanced CT or positive enhanced CT, respectively.

Second, the 3 tests of YiDiXie™ test can significantly relieve clinicians' work pressure and facilitate on-time diagnosis and timely treatment of malignant tumor cases that would otherwise be delayed. On the one hand, YiDiXie™-SS can significantly alleviate the non-essential work pressure of imaging physicians and surgeons. When an ultrasound is positive, the patient usually undergoes an enhanced CT, the timely completion of which is directly dependent on the number of imaging physicians. In many parts of the world, appointments are made for months or even more than a year. This inevitably delays the treatment of malignant cases among them, and thus it is not uncommon for patients with ultrasound-positive renal tumors awaiting enhanced CT to show malignant progression or even distant metastases. As shown in Table 3, YiDiXie™-SS reduces the false-positive rate of 66.2% (95% CI: 54.0% - 76.5%; 43/65) in patients with positive renal ultrasound with essentially no increase in malignant tumor leakage. This significantly reduces non-essential workload stress for imaging physicians.

YiDiXie™-SS also relieves surgeons of non-essential work significantly. Patients with renal tumors that are positive on enhanced CT usually undergo surgery. The timely completion of these surgeries is directly dependent on the number of surgeons. In many parts of the world, appointments are booked for months or even more than a year. This inevitably delays the treatment of malignant cases among them, and thus it is not uncommon for patients with renal tumors awaiting surgery to develop malignant progression or even distant metastases. Compared with the application of enhanced CT alone, sequential use of YiDiXie™-SS and CT had comparable sensitivity, but the

false-positive rate was reduced from 21.5% (95% CI: 13.3% - 33.0%; 14/65) to 6.2% (95% CI: 2.4% - 14.8%; 4/65) (Tables 2 and 5), decreasing enhanced CT's 71.4% false positive rate. This significantly relieves surgeons from non-essential work. As a result, YiDiXie™-SS can greatly relieve the stress of non-essential work for imaging physicians and surgeons, facilitating timely diagnosis and treatment of renal tumors or other diseases that would otherwise be delayed.

On the other hand, YiDiXie™-HS and YiDiXie™-D can greatly relieve clinicians' work pressure. In cases of difficult diagnosis by enhanced CT, this patient usually requires an enhanced MRI or puncture biopsy. The timely completion of these enhanced MRIs or renal puncture biopsies is directly dependent on the number of clinicians available. Appointments are available for months or even more than a year in many areas of the world. It is not uncommon for patients with renal tumors waiting for an enhanced MRI or puncture biopsy to experience malignant progression or even distant metastasis. YiDiXie™-HS and YiDiXie™-D can be used as alternatives to these enhanced MRIs or puncture biopsies, greatly relieving clinicians of their workloads and facilitating timely diagnosis and treatment of other tumors that would otherwise be delayed.

Final, the YiDiXie™ test enables "just-in-time" diagnosis of renal tumors. On the one hand, the YiDiXie™ test requires only microscopic amounts of blood, allowing patients to complete the diagnostic process non-invasively without having to leave their homes. A single YiDiXie™ test requires only 20 microliters of serum, which is equivalent to the volume of 1 drop of whole blood (1 drop of whole blood is about 50 microliters, which produces 20-25 microliters of serum)¹⁶. Considering the pre-test sample quality assessment experiments and 2-3 repeat experiments, 0.2 ml of whole blood is sufficient to complete the YiDiXie™ test¹⁶. The 0.2 ml of finger blood can be collected at home using a finger

blood collection needle, eliminating the need for venous blood collection by medical personnel and allowing patients to complete the diagnostic process non-invasively without having to leave their homes¹⁶.

On the other hand, the diagnostic capacity of the YiDiXie™ test is nearly limitless. Figure 1 shows the basic flow chart of the YiDiXie™ test, which shows that the YiDiXie™ test requires neither a doctor or medical equipment, nor medical personnel to collect blood. Therefore, the YiDiXie™ test is completely independent of the number of

medical personnel and medical facilities, and its testing capacity is nearly unlimited. Thus, the YiDiXie™ test enables "just-in-time" diagnosis of renal tumors without the patient having to wait anxiously for an appointment.

In short, YiDiXie™ test has an significant diagnostic value in renal tumors, and is expected to solve the three problems of renal tumors, namely, "high false-positive rate of ultrasound", "high false-negative rate of enhanced CT" and "high false-positive rate of enhanced CT".




Figure 1. Basic flowchart of the "YiDiXie™ test".

Limitations of the study

First, the number of cases in this study was relatively small, and larger sample size clinical studies are needed for further evaluation in the future.

Second, this study was a malignant tumor case-benign tumor control study in hospitalized patients, and a cohort study in the natural

population of renal tumors is needed for further evaluation in the future.

Last, this study was a single-center study, which may have led to some degree of bias in the results of this study. A multi-center study is needed in the future to further assess the results.

CONCLUSION

YiDiXie™ -SS dramatically reduces the false-positive rate of ultrasound and enhanced CT with essentially no increase in delayed treatment of malignant tumors. YiDiXie™ -HS dramatically reduces the false-negative rate of enhanced CT. YiDiXie™ -D dramatically reduces the false-positive

rate of enhanced CT. The YiDiXie™ test has significant diagnostic value in renal tumors, and is expected to solve the 3 problems of "high false-positive rate of ultrasound", "high false-negative rate of enhanced CT" and "high false-positive rate of enhanced CT".

FUNDING

This study was supported by Shenzhen High-level Hospital Construction Fund, Clinical Research Project of Peking University Shenzhen

Hospital (LCYJ2020002, LCYJ2020015, LCYJ2020020, LCYJ2017001).

REFERENCES

1. Motzer R J, Jonasch E, Agarwal N, et al. Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology [J]. Journal of the National Comprehensive Cancer Network, 2022, 20(1): 71-90.
2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2024.
3. Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries [J]. CA: A Cancer Journal for Clinicians, 2021, 71(3): 209-49.
4. Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update [J]. European Urology, 2022, 82(4): 399-410.
5. Bukowski R M. Natural history and therapy of metastatic renal cell carcinoma [J]. Cancer, 1997, 80(7): 1198-220.
6. Network NCC. NCCN Clinical Practice Guidelines in Oncology Kidney Cancer Version 4.2024 [J]. 2024.
7. Capitanio U, Bensalah K, Bex A, et al. Epidemiology of Renal Cell Carcinoma [J]. European Urology, 2019, 75(1): 74-84.
8. STEPHENSON A J, KURITZKY L, CAMPBELL S C. Screening for urologic malignancies in primary care: Pros, cons, and recommendations [J]. CLEVELAND CLINIC JOURNAL OF MEDICINE, 2007, 74.
9. Rossi S H, Klatte T, Usher-Smith J, et al. Epidemiology and screening for renal cancer [J]. World Journal of Urology, 2018, 36(9): 1341-53.
10. CA Jamis-Dow, PL Choyke, SB Jennings, et al. Small (< or= 3-cm) renal masses: detection with CT versus US and pathologic correlation. [J]. Radiology, 1996.
11. Schmidt T, Hohl C, Haage P, et al. Diagnostic Accuracy of Phase- InversionTissue Harmonic Imaging Versus Fundamental B-Mode Sonography in the Evaluation of Focal Lesions of the Kidney [J]. American Journal of Roentgenology, 2003.
12. Corcoran A T, Russo P, Lowrance W T, et al. A Review of Contemporary Data on Surgically Resected Renal Masses—Benign or Malignant? [J]. Urology, 2013, 81(4): 707-13.
13. Borghesi M, Brunocilla E, Volpe A, et al. Active surveillance for clinically localized renal tumors: An updated review of current indications and clinical outcomes [J]. International Journal of Urology, 2015, 22(5): 432-8.
14. Kim J H, Sun H Y, Hwang J, et al. Diagnostic accuracy of contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging of small renal masses in real practice: sensitivity and

specificity according to subjective radiologic interpretation [J]. World Journal of Surgical Oncology, 2016, 14(1).

15. Wildberger J E, Adam G, Boeckmann W, et al. Computed Tomography Characterization of Renal Cell Tumors in Correlation with Histopathology [J]. Investigative Radiology, 1997, 32(10): 596-601.
16. Chen Sun, Chong Lu, Yongjian Zhang, et al. Evaluation of the Multi-Cancer Early Detection (MCED) value of YiDiXie™-HS and YiDiXie™-SS [J]. medRxiv, 2024: doi: 10.1101/2024.03.11.24303683.
17. Edge SB and Compton CC: The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Annals of Surgical Oncology. 17: 1471-1474, 2010.
18. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and Winchester DP: The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA: A Cancer Journal for Clinicians. 67: 93-99, 2017.